[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Jung DI, Kim HJ, Park C, Kim JW, Kang BT, Lim CY, Park EH, Sur JH, Seo MH, Hahm DH, Park HM: Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer. J Vet Med Sci; 2006 Apr;68(4):383-6
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer.
  • A mass in the diencephalon was noted on brain magnetic resonance images.
  • Based on diagnostic image analysis, this lesion strongly suggested meningioma.
  • The patient's symptoms were well controlled by a combination therapy of prednisolone and lomustine (CCNU), and survived for thirteen months after diagnosis.
  • This case was diagnosed as a meningioma based on histopathological findings.
  • This report describes the clinical findings, imaging characteristics, and pathologic features of a diencephalic and mesencephalic meningioma and long-term survival after lomustine and prednisolone therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679732.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 7BRF0Z81KG / Lomustine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


2. Chamberlain MC, Glantz MJ: Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer; 2008 Oct 15;113(8):2146-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
  • BACKGROUND: Intracranial meningiomas are common, they frequently recur after surgery or radiotherapy, and there are limited data regarding the treatment of intracranial meningiomas with chemotherapy.
  • A phase 2 study was designed to estimate the 6-month progression-free survival of patients with recurrent, treatment-refractory, World Health Organization grade 1 meningiomas who were treated with interferon-alpha.
  • METHODS: Thirty-five patients with recurrent meningiomas ranging in age from 36 years to 88 years (median age, 61 years) were treated according to a prospective phase 2 study.
  • All patients had received prior surgery, radiotherapy, (involved-field radiotherapy in 35 patients andstereotactic radiotherapy in 22 patients), and chemotherapy (hydroxyurea in 19 patients and other in 17 patients).
  • A complete blood count and chemistry panel was obtained before every cycle, and cranial magnetic resonance images were obtained every 3 months.
  • There were no treatment-related deaths or delays in therapy reported.
  • The median time to tumor progression was 7 months (range, 2-24 months).
  • CONCLUSIONS: Treatment with interferon-alpha for recurrent meningiomas was found to be tolerated moderately well and was modestly effective.
  • [MeSH-major] Interferon-alpha / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18756531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


3. Evans DG: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis; 2009;4:16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 (NF2): a clinical and molecular review.
  • Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development of multiple schwannomas and meningiomas.
  • The other main tumours are schwannomas of the other cranial, spinal and peripheral nerves; meningiomas both intracranial (including optic nerve meningiomas) and intraspinal, and some low-grade central nervous system malignancies (ependymomas).
  • Neurofibromatosis type 2 is a dominantly inherited tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22.
  • A strategy for detection of the latter is vital for a sensitive analysis.
  • Diagnosis is based on clinical and neuroimaging studies.
  • Prenatal diagnosis and pre-implantation genetic diagnosis is possible.
  • The main differential diagnosis of NF2 is schwannomatosis.
  • Surgery remains the focus of current management although watchful waiting with careful surveillance and occasionally radiation treatment have a role.
  • Prognosis is adversely affected by early age at onset, a higher number of meningiomas and having a truncating mutation.
  • In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating condition.


Advertisement
4. Falavigna A, Santos JA, Chimelli L, Ferraz FA, Bonatelli Ad Ade P: Anaplastic meningioma: case report. Arq Neuropsiquiatr; 2001 Dec;59(4):939-43
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: case report.
  • Intracranial meningiomas continue to challenge our best clinical efforts to eliminate them once discovered and deemed appropriate for treatment.
  • Malignant meningiomas constitute 10% to 15% of all meningiomas and limited information exists regarding adjuvant treatment.
  • The external whole brain irradiation is recommended.
  • Traditional chemotherapy has proven ineffective; thus, new chemotherapeutic agents and new methods of delivery should be developed.
  • Immunotherapy may be considered for patients with malignant meningiomas when all others previous treatment have failed.
  • We report a case of anaplastic papillary meningioma.
  • A computerized tomography and magnetic resonance image demonstrated a large left temporo-occipital mass with diffuse contrast enhancement and extensive surrounding edema.
  • The treatment was complemented by external whole brain radiation.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11733842.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 28
  •  go-up   go-down


5. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • The interval between the onset of the intracranial disease and the appearance of the metastasis varies from months to many years.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Chamberlain MC, Glantz MJ: Cerebrospinal fluid-disseminated meningioma. Cancer; 2005 Apr 1;103(7):1427-30
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid-disseminated meningioma.
  • BACKGROUND: Intracranial meningiomas are common and comprise 20% of all primary brain tumors.
  • Meningiomas infrequently metastasize; however, to the authors' knowledge there are limited data regarding the spread of disease through cerebrospinal fluid (CSF).
  • METHODS: Eight of 200 consecutive patients (4%) with meningiomas manifested CSF dissemination.
  • All patients had undergone prior surgery (range, one to five surgeries; median, two surgeries), radiotherapy (involved-field radiotherapy in seven patients and stereotactic radiotherapy in six patients), and chemotherapy (hydroxyurea in eight patients).
  • Multiple sites of metastases were seen in all patients and were both within the nervous system (subarachnoid or ventricular tumor: intracranial in eight patients, spinal cord in four patients) and extraneural (subcutaneous, cervical lymph nodes, orbit, or pulmonary in five patients).
  • Treatment utilized both systemic chemotherapy (temozolomide in four patients, irinotecan in three patients, hydroxyurea in three patients, interferon-alpha in two patients, and doxorubicin plus ifosfamide in one patient) and intraventricular chemotherapy (liposomal cytosine arabinoside in seven patients, thiotepa in one patient, and busulfan in one patient).
  • RESULTS: Treatment-related toxicity was seen in eight patients, including chemical meningitis in eight patients (Grade 2), neutropenia in five patients (Grade 2 in four patients and Grade 3 in one patient), fatigue in one patient (Grade 2), and gastrointestinal toxicity in one patient (Grade 2).
  • The median survival was 5.5 months, and 3 patients were alive with disease at the time of last follow-up.
  • CONCLUSIONS: The treatment of CSF-disseminated meningioma, although feasible and comparatively nontoxic, was associated with modest outcomes despite combined systemic and intraventricular chemotherapy.
  • [MeSH-major] Meningioma / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Cerebrospinal Fluid / cytology. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Skin Neoplasms / secondary. Spinal Cord Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15690330.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Bodner-Adler B, Lozano P, Bodner K, Zeisler H: Primary uterine leiomyosarcoma and primary atypical meningioma diagnosed during pregnancy. Anticancer Res; 2008 Sep-Oct;28(5B):3083-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary uterine leiomyosarcoma and primary atypical meningioma diagnosed during pregnancy.
  • The incidence of meningioma during pregnancy is comparable with that in nonpregnant women of the same age group.
  • We report a case of both--a primary uterine leiomyosarcoma and additionally an atypical meningioma of the brain both diagnosed during pregnancy.
  • A tumoural mass was detected and initial conservative treatment was started.
  • During caesarean section a pedunculated uterine fibroid was removed and total gross resection due to the brain tumour was also performed.
  • Histopathological diagnosis of both tumours revealed an atypical meningioma of the brain and a uterine leiomyosarcoma.
  • The patient underwent laparatomy and received six cycles of adjuvant chemotherapy.
  • Treatment options seem to be reduced in pregnant women and mainly depend on the patient's condition as well as the gestational age at presentation.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Meningioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Uterine Neoplasms / diagnosis


8. Palmer JD, Francis JL, Pickard JD, Iannotti F: The efficacy and safety of aprotinin for hemostasis during intracranial surgery. J Neurosurg; 2003 Jun;98(6):1208-16
Hazardous Substances Data Bank. APROTININ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of aprotinin for hemostasis during intracranial surgery.
  • One hundred patients with a preoperative diagnosis of intracranial meningioma or vestibular schwannoma subsequently confirmed on histological studies were included.
  • All patients were older than 18 years of age, pregnancy had been excluded, there was no history of bleeding diathesis, no previous exposure to aprotinin, and no ingestion of antiplatelet or anticoagulant medications within the 2 weeks preceding surgery.
  • There were no significant differences in postoperative thrombotic risk or other outcome measures between treatment groups.
  • Aprotinin therefore can be safely used to reduce intraoperative blood loss in patients who are not receiving anticoagulation therapy.
  • [MeSH-minor] Blood Transfusion / statistics & numerical data. Cognition / drug effects. Double-Blind Method. Drug Administration Schedule. Female. Humans. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Neuropsychological Tests. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Apr;102(4):757-8; author reply 758 [15871522.001]
  • (PMID = 12816266.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics; 9087-70-1 / Aprotinin
  •  go-up   go-down


9. Dashti SR, Sauvageau E, Smith KA, Ashby LS: Nonsurgical treatment options in the management of intracranial meningiomas. Front Biosci (Elite Ed); 2009;1:494-500
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical treatment options in the management of intracranial meningiomas.
  • Surgical resection is the treatment of choice for most intracranial meningiomas.
  • We review the current state of adjuvant therapies, including radiation and chemotherapy.
  • Radiation therapy is most useful in the setting of recurrent or residual tumor after surgical resection, where it is associated with a clear increase in the length of progression-free survival.
  • This survival advantage is most pronounced with high-grade meningiomas, which have a much higher recurrence rate than low-grade meningiomas, even after gross total resection.
  • In contrast, the role of chemotherapy in the treatment of meningiomas is limited.
  • This treatment modality is often reserved for inoperable tumors or those refractory to radiation treatment.
  • Furthermore, the choice of chemotherapy agents is limited.
  • Hydroxyurea, a ribonucleotide reductase inhibitor, has modest clinical activity in meningiomas.
  • [MeSH-major] Hydroxyurea / therapeutic use. Meningioma / drug therapy. Meningioma / radiotherapy. Meningioma / surgery. Radiosurgery / methods. Somatostatin / therapeutic use
  • [MeSH-minor] Humans. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482663.001).
  • [ISSN] 1945-0508
  • [Journal-full-title] Frontiers in bioscience (Elite edition)
  • [ISO-abbreviation] Front Biosci (Elite Ed)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


10. Lin JW, Su FW, Wang HC, Lee TC, Ho JT, Lin CH, Lin YJ: Breast carcinoma metastasis to intracranial meningioma. J Clin Neurosci; 2009 Dec;16(12):1636-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma metastasis to intracranial meningioma.
  • Meningiomas and breast cancers are common tumors among women in the fifth to seventh decade.
  • However, metastasis from breast cancer to an intracranial meningioma is rare.
  • At that time, the pathological diagnosis was infiltrating ductal carcinoma.
  • She required adjuvant radiotherapy and chemotherapy for a local recurrence 7 years later.
  • On admission to our hospital, cranial CT scans showed a brightly enhancing, irregularly shaped lesion over the left high parietal lobe with surrounding parenchymal edema.
  • Histopathological examination of the lesion revealed two distinct tumor types, meningioma and metastatic carcinoma of breast tissue origin.
  • Although meningiomas have well-known radiological features, other tumors, including metastases from breast cancers may simulate them.
  • In the clinical setting of previously diagnosed breast cancer, prompt craniotomy for removal of meningioma-like intracranial lesions is recommended to avoid missing the diagnosis of breast cancer metastasis which carries a poorer prognosis than meningioma and requires a different treatment strategy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Meningeal Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Keratins / metabolism. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766009.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


11. Pozzati E, Zucchelli M, Schiavina M, Contini P, Foschini MP: Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report. Surg Neurol; 2007 Dec;68(6):671-4; discussion 674-5
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report.
  • It has been suggested that estrogens play a role in its evolution, and progesterone therapy is often provided in these cases.
  • CASE DESCRIPTION: We present a case of a postmenopausal woman with LAM treated with progesterone; subsequently, rapid growth of multiple intracranial meningiomas was observed.
  • CONCLUSIONS: This is a rare case of a non-pregnancy-related regression of meningiomas in a woman affected by LAM.
  • The significance of this association and the hormonal treatment of the disease are discussed.
  • [MeSH-major] Lymphangioleiomyomatosis / drug therapy. Meningeal Neoplasms / chemically induced. Meningioma / chemically induced. Progesterone / adverse effects. Progestins / adverse effects

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586005.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


12. Strassner C, Buhl R, Mehdorn HM: Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res; 2009 Jun;31(5):478-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
  • OBJECTIVE: Meningiomas are benign intracranial tumors growing from the arachnoid cap cells.
  • METHODS: Between 1991 and 2002, 463 patients with an intracranial meningioma were operated in the Department of Neurosurgery, University of Kiel, Kiel, Germany.
  • We compared the outcome of these patients after operation and the different methods of radiation therapy and chemotherapy with the data from Buhl (1994), who analysed 661 patients with intracranial meningioma who were operated on in the Department of Neurosurgery, University of Essen, Essen, Germany, between 1968 and 1988, to find out whether better methods of diagnosis like magnetic resonance imaging scans, magnetic resonance spectroscopy, post-operative radiation therapy and chemotherapy have an influence on the recurrence and outcome after surgical treatment.
  • Both studies underlined the preponderance of female patients for intracranial meningiomas.
  • The intracranial localization of the meningiomas was similar to the distribution of the histological subtypes and the rate of recurrence; only the malignant meningiomas showed a higher grade of recurrence in the last study.
  • Indications for post-operative radiation therapy were given earlier in the last study owing to the experience from the primary study.
  • The outcome of the patients after surgical removal was improving in the last years; the 30 day post-operative mortality after a primary operation on an intracranial meningioma decreased from 12.1 to 3%.
  • After removal of a recurrent meningioma, the mortality declined from 20 to 12.5%.
  • CONCLUSION: In the last 30 years, nothing important changed at the time of appearance of meningiomas, concerning the gender distribution and localisation as well as histological subtypes.
  • With better operating modalities and additional treatment with radiation and gamma knife, the mortality decreased significantly from 12 to 3% and the outcome of the patients is still improving, so that even elderly patients with intracranial meningioma can undergo surgical treatment with minor risks.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiosurgery. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500450.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Kunikata H, Tamai M: Cilioretinal artery occlusions following embolization of an artery to an intracranial meningioma. Graefes Arch Clin Exp Ophthalmol; 2006 Mar;244(3):401-3
Hazardous Substances Data Bank. POLYVINYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cilioretinal artery occlusions following embolization of an artery to an intracranial meningioma.
  • PURPOSE: To report a case in which a prophylactic embolization of a feeder artery to an intarcranial meningioma led to an occlusion of a cilioretinal artery.
  • METHODS: A 48-year-old man with an intracranial meningioma presented with ocular pain and visual loss in his right eye following embolization of a feeder artery to the meningioma with polyvinyl alcohol.
  • CONCLUSIONS: Our case demonstrated that an occlusion of a retinal artery can be a complication of preoperative embolization of an artery to an intracranial tumor and can lead to severe visual loss.
  • [MeSH-major] Chemoembolization, Therapeutic / adverse effects. Ciliary Arteries / pathology. Meningeal Arteries / drug effects. Meningeal Neoplasms / therapy. Meningioma / therapy. Retinal Artery Occlusion / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1991 Apr;98 (4):527-31 [2052308.001]
  • [Cites] Am J Ophthalmol. 2004 Sep;138(3):496-8 [15364244.001]
  • [Cites] Am J Ophthalmol. 2000 May;129(5):690-1 [10844076.001]
  • [Cites] Am J Ophthalmol. 1985 May 15;99(5):586-9 [4003497.001]
  • [Cites] Arch Ophthalmol. 2002 Jun;120(6):857-60 [12049601.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Dec;77(6):717-8 [10634572.001]
  • [Cites] J Neurosurg. 1974 Sep;41(3):396-8 [4415192.001]
  • (PMID = 16059705.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down


14. Sessums K, Mariani C: Intracranial meningioma in dogs and cats: a comparative review. Compend Contin Educ Vet; 2009 Jul;31(7):330-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma in dogs and cats: a comparative review.
  • Meningiomas are extraaxial tumors that arise from the arachnoid layer of the meninges.
  • Meningiomas in both species grow slowly and have an insidious onset of clinical signs.
  • Surgery, radiation, and chemotherapy can target the primary tumor, whereas steroids and anticonvulsants are confined to treating secondary effects of the tumor.
  • If the meningioma cannot be resected in its entirety, radiation therapy can increase survival time.
  • [MeSH-major] Cat Diseases / diagnosis. Dog Diseases / diagnosis. Meningeal Neoplasms / veterinary. Meningioma / veterinary
  • [MeSH-minor] Animals. Breeding. Cats. Dogs. Prognosis. Risk Factors. Species Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746352.001).
  • [ISSN] 1940-8315
  • [Journal-full-title] Compendium (Yardley, PA)
  • [ISO-abbreviation] Compend Contin Educ Vet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


15. Chamberlain MC, Blumenthal DT: Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother; 2004 Jul;4(4):641-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: diagnosis and treatment.
  • Meningiomas are extra-axial CNS tumors which have a female predominance and occur in middle-to-late adult life.
  • Most meningiomas (90%) are benign, 6% are atypical and a small proportion (2%) are malignant.
  • Most patients diagnosed with a meningioma undergo surgical resection to relieve neurological symptoms.
  • Advocates of stereotactic radiotherapy have suggested this therapy in lieu of surgery particularly in poor surgical risk patients, patients with meningiomas in eloquent or surgically inaccessible locations and in patients of advanced age.
  • When the meningioma is unresectable or all other treatments (e.g., surgery and radiotherapy) have failed, hormonal chemotherapy may be considered.
  • Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853583.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


16. Benedetto N, Perrini P, Scollato A, Buccoliero AM, Di Lorenzo N: Intracranial meningioma containing metastatic colon carcinoma. Acta Neurochir (Wien); 2007 Aug;149(8):799-803; discussion 803
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma containing metastatic colon carcinoma.
  • Meningioma is the most common intracranial tumour to host metastases, the majority of which arise from breast and lung cancers.
  • We present the first report of a colonic cancer metastasis within an intracranial meningioma.A 76-year-old woman presented with a one month history of partial seizures.
  • Her medical history included resection of an adenocarcinoma of the descending colon followed by adjuvant chemotherapy 1 year before our evaluation.
  • The pathological examination demonstrated a mixture of fibrous meningioma and colloid adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Meningeal Neoplasms / secondary. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Aged. Colectomy. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660939.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


17. Andersen C: [Intracranial meningioma. New knowledge]. Ugeskr Laeger; 2001 May 7;163(19):2618-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial meningioma. New knowledge].
  • Meningiomas are classified according to WHO (1993), and include eleven subtypes of benign meningiomas, two semi-malignant and one anaplastic.
  • In most cases meningiomas exhibit modifications or deletions in chromosome 22.
  • Increasing knowledge of the natural history concerning growth rate and the treatment of incidental meningiomas is accumulating.
  • Meningiomas formerly classified as surgically inaccessible are now often operable due to a continuing refinement of the surgical techniques and the study of possible new routes of intracranial tumour removal.
  • [MeSH-major] Brain Neoplasms. Meningioma
  • [MeSH-minor] Chromosome Deletion. Chromosomes, Human, Pair 22. Combined Modality Therapy. Humans. Receptors, Cell Surface / drug effects. Receptors, Cell Surface / metabolism. Risk Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11360354.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Cell Surface
  • [Number-of-references] 38
  •  go-up   go-down


18. Rockhill J, Mrugala M, Chamberlain MC: Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus; 2007;23(4):E1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: an overview of diagnosis and treatment.
  • Meningiomas are extraaxial central nervous system tumors most often discovered in middle to late adult life, and are more often seen in women.
  • Ninety percent of meningiomas are benign, 6% are atypical, and 2% are malignant.
  • Most patients in whom a meningioma is diagnosed undergo resection to relieve neurological symptoms.
  • Radiotherapy may be administered as either conventional external-beam radiation therapy or stereotactically by linear accelerator, Leksell Gamma Knife, or Cyberknife radiosurgery.
  • Advocates of stereo-tactic radiotherapy have suggested this therapy in lieu of surgery particularly in high-risk patients, those with meningiomas in eloquent or surgically inaccessible locations, and elderly patients.
  • When the meningioma is unresectable or all other treatments (surgery and radiotherapy) have failed, hormonal therapy or chemotherapy may be considered.
  • Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961033.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


19. Stienen MN, Lücke S, Fournier JY, Hildebrandt G, Gautschi OP: [The intracranial meningioma - therapeutic possibilities and limitations]. Praxis (Bern 1994); 2010 Dec 1;99(24):1479-94
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The intracranial meningioma - therapeutic possibilities and limitations].
  • [Transliterated title] Das intrakranielle Meningeom - Therapeutische Möglichkeiten und Grenzen.
  • Meningiomas are common intracranial tumours that arise from arachnoidal cells.
  • Clinically they often manifest by headache, focal or generalized seizures, or neurologic deficits as a result of brain compression.
  • More than 90 percent of these mostly slow growing meningiomas are benign.
  • Stereotactic radiotherapy as initial treatment is an effective alternative for meningiomas, especially in patients not suitable for surgery due to various reasons.
  • In patients that are refractory to treatment or with unresectable disease a hormonal- or chemotherapy can be considered.
  • [MeSH-major] Meningeal Neoplasms / therapy
  • [MeSH-minor] Algorithms. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Cross-Sectional Studies. Humans. Magnetic Resonance Imaging. Prognosis. Radiosurgery. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21125533.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Travitzky M, Libson E, Nemirovsky I, Hadas I, Gabizon A: Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma. Anticancer Drugs; 2003 Mar;14(3):247-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma.
  • Metastatic meningioma is a rare disease, which has no effective chemotherapy.
  • We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation.
  • A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months with near-complete resolution of metastases and disappearance of pleural fluid.
  • The patient remains in near-complete response for 6 months after treatment discontinuation.
  • This is the first report on an effective chemotherapy in a patient with typical metastatic meningioma.
  • The exact mechanism accounting for such an effective drug action is not clear, but may be related to a particularly high microvascular permeability to the liposome carriers in these metastatic lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Lung Neoplasms / drug therapy. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Lippincott Williams & Wilkins
  • (PMID = 12634620.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Kashimura H, Inoue T, Ogasawara K, Arai H, Otawara Y, Kanbara Y, Ogawa A: Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging. J Neurosurg; 2007 Oct;107(4):784-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of meningioma consistency using fractional anisotropy value measured by magnetic resonance imaging.
  • OBJECT: Preoperative planning for meningiomas requires information about tumor consistency as well as location and size.
  • In the present study the authors aimed to determine whether the fractional anisotropy (FA) value calculated on the basis of preoperative magnetic resonance (MR) diffusion tensor (DT) imaging could predict meningioma consistency.
  • METHODS: In 29 patients with intracranial meningiomas, MR DT imaging was performed preoperatively, and the FA values of the tumors were calculated.
  • Tumor consistency was intraoperatively determined as hard or soft, and the histological diagnosis of the tumor was established.
  • The FA values of fibroblastic meningiomas were significantly higher than those of meningothelial meningiomas (p = 0.002).
  • CONCLUSIONS: The FA value calculated from preoperative MR DT imaging predicts meningioma consistency.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17937223.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. McDonnell JJ, Kalbko K, Keating JH, Sato AF, Faissler D: Multiple meningiomas in three dogs. J Am Anim Hosp Assoc; 2007 Jul-Aug;43(4):201-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple meningiomas in three dogs.
  • Three dogs with seizures were diagnosed with multiple intracranial meningiomas.
  • Treatment consisted of surgery and radiation (n=2) or chemotherapy (n=1).
  • In two dogs, the meningiomas had the same histological pattern, while in one dog the histological subtypes were different.
  • [MeSH-major] Dog Diseases / diagnosis. Meningeal Neoplasms / veterinary. Meningioma / veterinary. Seizures / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Female. Male

  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615400.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg; 2002 Aug;97(2):341-6
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
  • OBJECT: The management of certain meningiomas of the skull base and those involving the dural venous sinuses remains a challenge.
  • In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas.
  • The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.
  • METHODS: Hydroxyurea was administered at a dosage of approximately 20 mg/kg/day to 11 women and nine men (median age 59 years, range 31-75 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple).
  • In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant.
  • Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery.
  • Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.
  • All patients were evaluable for response to therapy.
  • In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8-151 weeks), and two of these showed clinical improvement.
  • One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations.
  • In three others with benign meningiomas, progression was confirmed on neuroimages obtained after 41, 55, and 66 weeks, respectively: the 1-year freedom from progression rate was 0.93 (standard error 0.07) in patients with benign meningiomas.
  • In three patients with atypical meningiomas, the tumors had progressed on neuroimages obtained after 12, 19, and 45 weeks, respectively.
  • In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks.
  • Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.
  • CONCLUSIONS: Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Disease Progression. Hydroxyurea / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / physiopathology. Meningioma / drug therapy. Meningioma / physiopathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / physiopathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Remission Induction. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186462.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


24. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ: Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol; 2009 Sep;256(9):1519-26
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
  • Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited.
  • An observational study was carried out using a database of all patients from the neuro-oncology service during the period 2000-2005, with data on seizure characteristics, therapy with AEDs, the underlying brain tumor and its treatment.
  • A total of 140 brain tumor patients were studied of whom 23.6% had a low-grade glioma, 53.6% a high-grade glioma, and 22.8% belonged to a mixed group existing of ependymoma, meningioma, and brain metastasis.
  • Epilepsy as the presenting sign was more frequent in low-grade vs. high-grade gliomas (69.7 vs. 52%, P = 0.087), and a total of 75.8% of patients developed seizures with low-grade and of 80.0% with high-grade gliomas.
  • This indicates that adding levetiracetam may be preferable over sequential trials of AED monotherapy in treatment-resistant seizures in patients with brain tumors.
  • [MeSH-major] Anticonvulsants / therapeutic use. Brain Neoplasms / complications. Glioma / complications. Seizures / drug therapy. Seizures / etiology
  • [MeSH-minor] Adult. Carbamazepine / therapeutic use. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Piracetam / analogs & derivatives. Piracetam / therapeutic use. Time Factors. Treatment Outcome. Triazines / therapeutic use. Valproic Acid / therapeutic use


25. Martin AJ, Hammond CJ, Dobbs HJ, Al-Sarraj S, Thomas NW: Spinal meningioma after treatment for Hodgkin disease. Case report. J Neurosurg; 2001 Oct;95(2 Suppl):232-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma after treatment for Hodgkin disease. Case report.
  • Long-term survivors of Hodgkin disease may develop second primary tumors caused by the mutagenic effects of radio- and chemotherapy.
  • The authors describe the case of a 35-year-old woman who presented with an unusual meningioma of the cervical spine 9 years after undergoing combined-modality treatment for Hodgkin disease.
  • To the authors' knowledge, this is the first report of spinal meningioma as a complication of such therapy.
  • Whereas radiation-induced intracranial meningiomas are well described in the literature, treatment-induced meningiomas of the spine have not been widely recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / therapy. Meningioma / etiology. Neoplasms, Second Primary. Spinal Neoplasms / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Female. Humans. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599842.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • And the imaging studies should include the field of the orbit, sinus, and brain to search for the primary lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


27. Batay F, Al-Mefty O: Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases. Acta Neurochir (Wien); 2002 Apr;144(4):365-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases.
  • BACKGROUND: Although multiple sclerosis (MS) is a common disease of the central nervous system, the association of intraparenchymal tumour has been rarely reported and the potential relationship between intracranial meningioma and MS has not been seriously analysed.
  • This report addresses the association of multiple sclerosis and intracranial meningioma and discusses the effect of interferon treatment on tumour progression.
  • CLINICAL PRESENTATION: We report two cases with multiple sclerosis, who developed meningioma four and twenty years after the diagnosis of MS was made.
  • Neither patient had a history of meningioma initially and both were being treated interferon when the meningioma was progressed.
  • FINDINGS: Histological examination of two cases revealed meningothelial meningioma.
  • CONCLUSIONS: We reported the association of multiple sclerosis and intracranial meningioma and observed the progression of the meningiomas during interferon treatment.
  • Although, we cannot exclude the coincidence between the two diseases we discussed suspicious relationship between the interferon treatment and the tumour progression.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. Adjuvants, Immunologic / therapeutic use. Interferon-beta / adverse effects. Interferon-beta / therapeutic use. Meningeal Neoplasms / pathology. Meningioma / pathology. Multiple Sclerosis / complications. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Disease Progression. Female. Humans. Interferon beta-1a. Interferon beta-1b. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. Interferon Beta-1b .
  • Hazardous Substances Data Bank. Interferon Beta-1a .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12021883.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 145155-23-3 / Interferon beta-1b; 77238-31-4 / Interferon-beta; XRO4566Q4R / Interferon beta-1a
  •  go-up   go-down


28. Cage TA, Lamborn KR, Ware ML, Frankfurt A, Chakalian L, Berger MS, McDermott MW: Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. J Neurooncol; 2009 May;93(1):151-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.
  • Patients with brain tumors including intracranial meningiomas are at increased risk for developing deep vein thrombosis (DVTs) and suffering thromboembolic events (VTEs).
  • Many surgeons are concerned that early use of low dose enoxaparin may increase the risk of intracranial hemorrhage which outweighs the benefit of DVT/VTE reduction.
  • We aimed to address concerns around the use of enoxaparin after meningioma resection in the development of postoperative intracranial hemorrhages and DVT/VTEs.
  • This is a retrospective review of 86 patients with intracranial meningiomas who underwent craniectomy and surgical resection of the mass, treated by one attending surgeon at UCSF Medical Center between 2000 and 2005.
  • Within 48 h after surgery patients treated 2003-2005 routinely received enoxaparin therapy unless there was documented intracranial hemorrhage, lumbar subarachnoid drain, enoxaparin hypersensitivity, or thrombocytopenia (n = 24).
  • These were compared to a cohort treated 2000-2002 who did not receive the drug (n = 62).
  • Enoxaparin therapy did not increase the incidence of intracranial hemorrhage following surgical meningioma resection and the incidence of DVTs/VTEs was 0% (n = 0) versus 4.8% (n = 3) in the non-enoxaparin group.
  • In this retrospective study, postoperative administration of enoxaparin following meningioma resection does not increase the risk of intracranial hematoma though enoxaparin administration may slightly decrease the incidence of post-surgical thromboembolic events.
  • [MeSH-major] Anticoagulants / therapeutic use. Enoxaparin / therapeutic use. Meningeal Neoplasms / complications. Meningioma / complications. Postoperative Complications / prevention & control. Thrombosis / prevention & control
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Incidence. Intracranial Hemorrhages / epidemiology. Male. Middle Aged. Neurosurgical Procedures. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1977 Jul;47(1):27-30 [864504.001]
  • [Cites] Surg Neurol. 2002 Apr;57(4):241-51; discussion 251-2 [12173391.001]
  • [Cites] Acta Neurochir (Wien). 1986;80(3-4):83-9 [2424279.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1310-8 [16525187.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Neurol Res. 2004 Jan;26(1):61-6 [14977059.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1028-34; discussion 1034-5 [14580268.001]
  • [Cites] Thromb Haemost. 1996 Feb;75(2):233-8 [8815566.001]
  • [Cites] Surg Neurol. 2007 Oct;68(4):407-11; discussion 411 [17586023.001]
  • [Cites] Oncol Nurs Forum. 2007 Jul;34(4):777-82 [17723979.001]
  • [Cites] Chest. 2002 Dec;122(6):1933-7 [12475829.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1074-81 [9802851.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):830-2; discussion 832-3 [1614582.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):300-5 [17154163.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):378-81 [681999.001]
  • [Cites] J Neurosurg. 2001 Jun;94(6):918-21 [11409520.001]
  • [Cites] Acta Neurochir (Wien). 1991;109(3-4):93-7 [1858538.001]
  • [Cites] J Neurol. 1975 Jul 2;209(3):217-24 [51062.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):80-5 [9654538.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):299-307 [11981275.001]
  • (PMID = 19430892.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin
  •  go-up   go-down


29. Choi D, Seex K: Intracranial meningioma following childhood irradiation for leukaemia. Br J Haematol; 2000 Mar;108(4):665
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma following childhood irradiation for leukaemia.
  • [MeSH-major] Meningeal Neoplasms / radiography. Meningioma / radiography. Neoplasms, Second Primary / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Child, Preschool. Cranial Irradiation / adverse effects. Female. Humans. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792267.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement